Cargando…

Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?

The pursuit for blood a substitute has spanned over a century, but a majority of the efforts have been disappointing. As of today, there is no widely accepted product used as an alternative to human blood in clinical settings with severe anemic condition(s). Blood substitutes are currently also term...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lin, Yang, Zeyong, Liu, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962799/
https://www.ncbi.nlm.nih.gov/pubmed/36837597
http://dx.doi.org/10.3390/medicina59020396
_version_ 1784896092750479360
author Chen, Lin
Yang, Zeyong
Liu, Henry
author_facet Chen, Lin
Yang, Zeyong
Liu, Henry
author_sort Chen, Lin
collection PubMed
description The pursuit for blood a substitute has spanned over a century, but a majority of the efforts have been disappointing. As of today, there is no widely accepted product used as an alternative to human blood in clinical settings with severe anemic condition(s). Blood substitutes are currently also termed oxygen therapeutics. There are two major categories of oxygen therapeutics, hemoglobin-based and perfluorocarbon-based products. In this article, we reviewed the most developed but failed products and products still in active clinical research in the category of hemoglobin-based oxygen carriers. Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued. Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union. OxyVita and Sanguinate are still undergoing active clinical studies. The field of oxygen therapeutics seems to be entering a phase of rapid growth in the coming 10–20 years.
format Online
Article
Text
id pubmed-9962799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99627992023-02-26 Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023? Chen, Lin Yang, Zeyong Liu, Henry Medicina (Kaunas) Review The pursuit for blood a substitute has spanned over a century, but a majority of the efforts have been disappointing. As of today, there is no widely accepted product used as an alternative to human blood in clinical settings with severe anemic condition(s). Blood substitutes are currently also termed oxygen therapeutics. There are two major categories of oxygen therapeutics, hemoglobin-based and perfluorocarbon-based products. In this article, we reviewed the most developed but failed products and products still in active clinical research in the category of hemoglobin-based oxygen carriers. Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued. Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union. OxyVita and Sanguinate are still undergoing active clinical studies. The field of oxygen therapeutics seems to be entering a phase of rapid growth in the coming 10–20 years. MDPI 2023-02-17 /pmc/articles/PMC9962799/ /pubmed/36837597 http://dx.doi.org/10.3390/medicina59020396 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Lin
Yang, Zeyong
Liu, Henry
Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
title Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
title_full Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
title_fullStr Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
title_full_unstemmed Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
title_short Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
title_sort hemoglobin-based oxygen carriers: where are we now in 2023?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962799/
https://www.ncbi.nlm.nih.gov/pubmed/36837597
http://dx.doi.org/10.3390/medicina59020396
work_keys_str_mv AT chenlin hemoglobinbasedoxygencarrierswherearewenowin2023
AT yangzeyong hemoglobinbasedoxygencarrierswherearewenowin2023
AT liuhenry hemoglobinbasedoxygencarrierswherearewenowin2023